Serum hepatitis B virus RNA levels as an early predictor of hepatitis B envelope antigen seroconversion during treatment with polymerase inhibitors
Top Cited Papers
- 25 November 2014
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of Hepatology
- Vol. 61 (1), 66-76
- https://doi.org/10.1002/hep.27381
Abstract
Hepatitis B envelope antigen (HBeAg) seroconversion represents an endpoint of treatment of chronic hepatitis B virus (HBV) infections. We have studied whether levels of serum HBV RNA during polymerase inhibitor treatment might be helpful for predicting HBeAg seroconversion. HBV RNA levels were determined in serial serum samples from 62 patients with chronic HBV infection (50 HBeAg positive). Patients received antiviral treatment for a mean duration of 30 ± 15 (range, 4‐64) months. A new rapid amplification of complimentary DNA‐ends‐based real‐time polymerase chain reaction was established for quantitative analysis of polyadenylated full‐length (fl) and truncated (tr) HBV RNA. HBV RNA, HBV DNA, and hepatitis B surface antigen (HBsAg) levels as well as presence of HBeAg and hepatitis B envelope antibody were measured at baseline, month 3, month 6, and subsequent time points. Fifteen patients who achieved HBeAg seroconversion after a mean duration of 19 ± 14 (range, 3‐56) months of antiviral treatment showed a significantly stronger decline in mean HBV flRNA and trRNA levels from baseline to month 3 of 1.0 ± 1.4 (range, −1.6‐3.4) and 2.1 ± 1.4 (range, 0‐3.9) and to month 6 of 1.8 ± 1.4 (range, 0‐4.6) and 3.1 ± 1.7 (range, 0‐5.1) log10 copies/mL, respectively, in comparison to 35 HBeAg‐positive patients without HBeAg seroconversion (P < 0.001 for months 3 and 6). A similar decline in HBV RNA levels was observed in HBeAg‐negative patients. The decline of HBV RNA levels at months 3 and 6 of treatment was to be the strongest predictor of HBeAg seroconversion, when compared to levels of HBV DNA, HBsAg, alanine aminotransferase, and HBV genotype, age, and sex. Conclusion: Serum HBV RNA levels may serve as a novel tool for prediction of serological response during polymerase inhibitor treatment in HBeAg‐positive patients. (Hepatology 2014)Keywords
This publication has 18 references indexed in Scilit:
- Telbivudine treatment is associated with high hepatitis B e antigen seroconversion and immune modulatory effects in chronic hepatitis B patientsJournal of Viral Hepatitis, 2013
- Efficacy and safety of continuous 4‐year telbivudine treatment in patients with chronic hepatitis BJournal of Viral Hepatitis, 2012
- Chronic hepatitis B: Update 2009Journal of Hepatology, 2009
- Hepatitis B virus infectionThe Lancet, 2009
- Hepatitis B Virus X‐DNAAnnals of the New York Academy of Sciences, 2008
- Serum HBV RNA is a predictor of early emergence of the YMDD mutant in patients treated with lamivudineJournal of Hepatology, 2007
- Management of hepatitis B: Summary of a clinical research workshopJournal of Hepatology, 2007
- Hepatitis B virus RNA is measurable in serum and can be a new marker for monitoring lamivudine therapyThe Esophagus, 2006
- Regularization and Variable Selection Via the Elastic NetJournal of the Royal Statistical Society Series B: Statistical Methodology, 2005
- Patterns of circulating hepatitis B virus serum nucleic acids during lamivudine therapyJournal of Medical Virology, 2003